HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

carlumab

targets CC-chemokine ligand 2; has antineoplastic activity

Also Known As:

CNTO 888; CNTO-888

Networked: 4 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Puchalski, Thomas A: 3 articles (03/2015 - 04/2013)
2.	Seetharam, Shobha: 3 articles (03/2015 - 04/2013)
3.	de Bono, Johann S: 2 articles (06/2013 - 04/2013)
4.	Agarwal, Prasheen: 1 article (12/2015)
5.	Barnathan, Elliot S: 1 article (12/2015)
6.	Brown, Kevin K: 1 article (12/2015)
7.	Costabel, Ulrich: 1 article (12/2015)
8.	Cottin, Vincent: 1 article (12/2015)
9.	Dasgupta, Bidisha: 1 article (12/2015)
10.	Flavin, Susan K: 1 article (12/2015)

Related Diseases

1.	Idiopathic Pulmonary Fibrosis 12/01/2015 - "The objective of this study was to determine the safety and efficacy of carlumab in the treatment of idiopathic pulmonary fibrosis (IPF).A phase 2, randomised, double-blind placebo-controlled dose-ranging study was conducted in patients with IPF (n=126). " 12/01/2015 - "CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab."
2.	Neoplasms (Cancer) 06/01/2013 - "Preclinical data suggest carlumab may offer clinical benefit to cancer patients. " 04/01/2013 - "Patients with advanced solid malignancy received escalating doses of carlumab 0.3, 1, 3, 10, or 15 mg/kg by 90-min intravenous infusion on days 1, 28, and every 2 weeks thereafter (dose escalation) or 10 or 15 mg/kg every 2 weeks (dose-expansion). " 03/01/2015 - "Carlumab could be safely administered at 10 or 15 mg/kg in combination with standard-of-care chemotherapy and was well-tolerated, although no long-term suppression of serum CCL2 or significant tumor responses were observed. " 03/01/2015 - "Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study." 04/01/2013 - "A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors."
3.	Prostatic Neoplasms (Prostate Cancer) 06/01/2013 - "In a phase 2, open-label study, patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel received a 90-min infusion of 15 mg/kg carlumab q2w. " 06/01/2013 - "Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer."
4.	Vomiting 04/01/2013 - "Carlumab-related adverse events included grade 1-2 fatigue (9 %), nausea (7 %), headache (7 %), vomiting (5 %), and pruritus (5 %). "
5.	Pruritus (Itching) 04/01/2013 - "Carlumab-related adverse events included grade 1-2 fatigue (9 %), nausea (7 %), headache (7 %), vomiting (5 %), and pruritus (5 %). "

Related Drugs and Biologics

1.	CC Chemokines
2.	Ligands
3.	carlumab
4.	Monoclonal Antibodies
5.	Docetaxel (Taxotere)
6.	Dihydrotachysterol (AT 10)
7.	Antibodies

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Castration
3.	Intravenous Infusions